| # | Title | Journal | Year | Citations |
|---|
| 1 | The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Blood | 2016 | 7,429 |
| 2 | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) | Blood | 2010 | 805 |
| 3 | Mutations and prognosis in primary myelofibrosis | Leukemia | 2013 | 653 |
| 4 | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial | Blood | 2014 | 428 |
| 5 | A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q | Blood | 2011 | 424 |
| 6 | Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis | Blood | 2014 | 340 |
| 7 | A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications | Leukemia | 2010 | 321 |
| 8 | Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms | Blood | 2013 | 290 |
| 9 | Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo | Cancer Cell | 2014 | 272 |
| 10 | The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Leukemia | 2014 | 263 |
| 11 | A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis | Leukemia | 2017 | 242 |
| 12 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome | Blood | 2013 | 208 |
| 13 | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Blood | 2012 | 205 |
| 14 | Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations | Blood | 2011 | 190 |
| 15 | From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms | Blood | 2014 | 174 |
| 16 | Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis | Blood | 2010 | 153 |
| 17 | Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria | Leukemia | 2012 | 149 |
| 18 | The genetics of nodal marginal zone lymphoma | Blood | 2016 | 147 |
| 19 | Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study | Haematologica | 2010 | 144 |
| 20 | Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis | Blood | 2009 | 135 |
| 21 | Recurrent ETNK1 mutations in atypical chronic myeloid leukemia | Blood | 2015 | 115 |
| 22 | Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network | Annals of Oncology | 2013 | 107 |
| 23 | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts | Blood | 2014 | 95 |
| 24 | Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults | HemaSphere | 2018 | 91 |
| 25 | The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts | Leukemia | 2013 | 89 |
| 26 | Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes | Hematology American Society of Hematology Education Program | 2008 | 84 |
| 27 | Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group | American Journal of Hematology | 2016 | 80 |
| 28 | The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection | Haematologica | 2015 | 73 |
| 29 | The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) | Annals of Oncology | 2014 | 67 |
| 30 | Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study | Leukemia | 2018 | 66 |
| 31 | The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis | Journal of Viral Hepatitis | 2016 | 61 |
| 32 | CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice | American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting | 2019 | 58 |
| 33 | Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy | Clinical and Developmental Immunology | 2012 | 55 |
| 34 | Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients | American Journal of Hematology | 2016 | 54 |
| 35 | The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) | American Journal of Hematology | 2015 | 49 |
| 36 | Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases | Thrombosis Research | 2014 | 47 |
| 37 | Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients | American Journal of Hematology | 2016 | 47 |
| 38 | Leukemia risk models in primary myelofibrosis: an International Working Group study | Leukemia | 2012 | 45 |
| 39 | Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study | Leukemia | 2016 | 44 |
| 40 | Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use | Leukemia and Lymphoma | 2014 | 40 |
| 41 | Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm | American Journal of Hematology | 2011 | 37 |
| 42 | Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes | Haematologica | 2020 | 35 |
| 43 | Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma) | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 32 |
| 44 | Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry | Haematologica | 2020 | 32 |
| 45 | A novel germline JAK2 mutation in familial myeloproliferative neoplasms | American Journal of Hematology | 2014 | 31 |
| 46 | Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project | Haematologica | 2018 | 31 |
| 47 | A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. | Blood | 2009 | 29 |
| 48 | Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence | Blood | 2013 | 29 |
| 49 | Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? | Therapeutic Advances in Hematology | 2016 | 26 |
| 50 | Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome | Journal of Internal Medicine | 2017 | 26 |
